Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) dropped 4.3% during trading on Thursday following insider selling activity. Get Halozyme Therapeutics alerts:Specifically, Director Bernadette Connaughton sold 2,000 shares of the business’s stock in a transaction on Wednesday, October 1st. The Goldman Sachs Group assumed coverage on shares of Halozyme Therapeutics in a report on Thursday, July 10th. As a group, equities research analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current year. Featured ArticlesReceive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.